ADMA Biologics, Inc. (NASDAQ:ADMA) Director Steve Elms Sells 183,008 Shares

ADMA Biologics, Inc. (NASDAQ:ADMAGet Free Report) Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $6.01, for a total value of $1,099,878.08. Following the completion of the sale, the director now directly owns 2,577,387 shares in the company, valued at $15,490,095.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Steve Elms also recently made the following trade(s):

  • On Wednesday, March 13th, Steve Elms sold 407,000 shares of ADMA Biologics stock. The stock was sold at an average price of $6.21, for a total value of $2,527,470.00.

ADMA Biologics Stock Down 0.5 %

Shares of NASDAQ:ADMA traded down $0.03 on Friday, hitting $5.99. 3,750,686 shares of the company’s stock were exchanged, compared to its average volume of 2,783,225. The firm’s 50-day moving average is $5.37 and its 200 day moving average is $4.32. The company has a market capitalization of $1.37 billion, a PE ratio of -46.08 and a beta of 0.43. ADMA Biologics, Inc. has a 1-year low of $2.94 and a 1-year high of $6.41. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ADMA shares. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of ADMA Biologics in a report on Thursday, February 29th. Mizuho boosted their target price on ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald boosted their target price on ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.50.

Get Our Latest Report on ADMA

Institutional Trading of ADMA Biologics

A number of large investors have recently made changes to their positions in ADMA. State Street Corp boosted its position in shares of ADMA Biologics by 217.9% in the 3rd quarter. State Street Corp now owns 9,423,422 shares of the biotechnology company’s stock valued at $22,899,000 after purchasing an additional 6,459,197 shares during the period. Millennium Management LLC boosted its position in shares of ADMA Biologics by 206.7% in the 4th quarter. Millennium Management LLC now owns 5,296,781 shares of the biotechnology company’s stock valued at $20,552,000 after purchasing an additional 3,569,778 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at about $12,658,000. Point72 Asset Management L.P. acquired a new stake in shares of ADMA Biologics in the 4th quarter valued at about $7,725,000. Finally, Stonepine Capital Management LLC raised its stake in ADMA Biologics by 38.8% during the 4th quarter. Stonepine Capital Management LLC now owns 6,940,000 shares of the biotechnology company’s stock valued at $26,927,000 after acquiring an additional 1,940,000 shares during the last quarter. 73.58% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

See Also

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.